President Biden’s Cancer Cabinet announces USPTO’s Cancer Immunotherapy Pilot Program

[[VIEW_THIS]]

President Biden’s Cancer Cabinet announces USPTO’s Cancer Immunotherapy Pilot Program

In furtherance of President Biden’s Cancer Moonshot initiative, the White House recently announced the United States Patent and Trademark Office’s (USPTO) recent renewal of our Cancer Immunotherapy Pilot Program. This program provides a fast-track review for cancer immunotherapy-related patent applications without the need for applicants to pay a petition fee. Under this program, patent applications pertaining to cancer immunotherapy are advanced out of turn for examination, resulting in their accelerated review, cutting in half the time it takes to review patent applications pertaining to cancer immunotherapy. The USPTO first implemented the program in June 2016, in support of the original Cancer Moonshot initiative.

The White House highlighted USPTO’s program renewal in an announcement on new members to the President’s Cancer Panel and priority actions of its Cancer Cabinet, which include closing the screening gap and bringing cutting edge research through the pipeline to patients and communities.  

Learn more in a recent White House fact sheet.

Stay connected with the USPTO by subscribing to regular email updates.

Visit our subscription center at www.uspto.gov/subscribe to update or change your email preferences.

This email was sent from an unmonitored mailbox. To contact us, please visit our website www.uspto.gov/about/contacts. To ensure that you continue to receive our news and notices, please modify your email filters to allow mail from subscriptioncenter@subscriptions.uspto.gov.